Abstract | The synovium is the major target tissue of inflammatory arthritides such as rheumatoid arthritis. The study of synovial tissue has advanced considerably throughout the past few decades from arthroplasty and blind needle biopsy to the use of arthroscopic and ultrasonographic technologies that enable easier visualization and improve the reliability of synovial biopsies. Rapid progress has been made in using synovial tissue to study disease pathogenesis, to stratify patients, to discover biomarkers and novel targets, and to validate therapies, and this progress has been facilitated by increasingly diverse and sophisticated analytical and technological approaches. In this Review, we describe these approaches, and summarize how their use in synovial tissue research has improved our understanding of rheumatoid arthritis and identified candidate biomarkers that could be used in disease diagnosis and stratification, as well as in predicting disease course and treatment response. NATURE REVIEWS | RHEUMATOLOGY VOLUME 13 | AUGUST 2017 | 463 REVIEWS © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
1
. For the purpose of this Review, we focus on rheumatoid arthritis (RA), owing to its prevalence and the fact that this disease is the most extensively studied and most common cause of synovitis. RA is usually persistent and progressive, and leads to joint damage, disability and deformity if left untreated. The disease is associated with a reduction in quality of life, as well as with decreased longevity, and represents an important burden on health care spending [2] [3] [4] . Within the past two decades, several considerable advances have been made in the treatment of inflammatory arthritides in general, and particularly in the treatment of RA. However, further progress is needed. The patterns of clinical response to treatment are remarkably similar for agents with different targets, and this finding challenges our current understanding of disease mechanisms. In addition, despite the aforementioned unprecedented progress, a substantial proportion of patients with RA still do not achieve a state of low disease activity or remission following treatment 5, 6 . The main challenges in biomedicine and translational research in RA are early diagnosis, personalized medicine and the development of meaningful outcome assessments 7 . A logical hypothesis is that each of these aims can be facilitated by the identification and development of appropriate biomarkers. However, although peripheral blood biomarkers such as rheumatoid factor and anti-citrullinated protein antibodies (ACPAs) have been shown to be relatively specific and might predict the development of RA in asymptomatic individuals 8 , they are reportedly found in only 70-80% of patients with RA 9 . Indeed, beyond rheumatoid factor and ACPAs, our repertoire of blood biomarkers to assist with diagnosis and to provide insights into disease progression and response to therapy is currently extremely limited 10, 11 . As the synovium is the principal target of inflammation in RA, and the resident fibroblast-like synoviocytes (FLSs) are implicated in the pathogenesis of synovitis, one promising approach could be to search for biomarkers in inflamed synovial tissue. Using a combination of established methodologies, together with new high-throughput omics technologies that have the capability to examine the expression of genes and their products on a scale never before possible
, a new opportunity awaits in the search for these biomarkers. This Review summarizes how synovial tissue research has advanced our understanding of RA, contributed to progress in addressing key challenges in the field and identified candidate biomarkers (TABLE 1) . We first briefly discuss the anatomy and physiology of the healthy synovial joint, the main changes that occur in the inflamed joint, and current approaches to biopsy retrieval and analysis.
Synovial joint anatomy and physiology
The synovial joint comprises opposing bones with articular surfaces that are covered by cartilage. The main protein in bone is type I collagen, whereas cartilage comprises mainly type II collagen and proteoglycan molecules. The non-articulating surfaces of synovial joints are lined by a thin adventitious layer known as the synovium. Normal synovial tissue comprises one to three layers of specialized columnar FLSs that are interspersed with macrophages 12 . The entire structure is enclosed by a fibrous capsule and, together with ligaments, muscles and tendons, the fibrous capsule confers strength and stability to the joint.
Several factors contribute to the maintenance of normal homeostasis in the synovial joint, including the expression of the protective lubricin 13 , the secretion of matrix metalloproteinases (MMPs) by FLSs, the immune sentinel roles of resident macrophages and FLSs, the regulated entry and exit of leukocytes involved in immune surveillance, and local regulation by cytokines and growth factors.
Cytokines and growth factors are important regulators of FLSs and chondrocytes [14] [15] [16] . Cytokines are categorized as either pro-inflammatory or anti-inflammatory depending on their immediate effects on specific tissues, although considerable potential exists for pleiotropism depending on the cells targeted and the microenvironment. Cytokines and growth factors are ubiquitous in the synovium and synovial space, and originate either from the plasma or from FLSs, chondrocytes and cells in the surrounding tissues 16 . The joint is a dynamic environment that is subject to minor trauma continually -owing to movement and, in some joints, compression due to weight bearingand is therefore subject to continued wound healing and repair processes. Continual remodelling of the articular cartilage and adjacent bone is therefore necessary, and this process requires a balance of anabolic and catabolic enzyme activity in both cartilage and bone. Carefully regulated proteolytic enzymes are responsible for maintaining the balance between anabolic and catabolic processes within the joint and cartilage 17 . The collagenases MMP1 (interstitial collagenase), MMP3 (stromelysin-1), MMP8 (neutrophil collagenase), MMP13 (collagenase 3) and MMP18 (also known as MMP19) are the most important of these enzymes, as they are the only known enzymes that can directly cleave collagen at a neutral pH 18 , but other MMPs contribute to collagen degradation once its triple helix structure has become unravelled 19 . Serine and cysteine proteinases are required to activate pro-MMPs (that is, MMP precursors) after they are secreted. Furthermore, inhibitors of these proteinases
• Synovial tissue is the target tissue for autoimmune arthritides such as rheumatoid arthritis.
• Synovial biopsy is a safe and well-tolerated procedure that is becoming more widely available.
• There is a significant body of work from the past 30 years analysing the cellular and molecular changes in synovial tissue from patients with rheumatoid arthritis to identify specific biomarkers.
• Technological advances in molecular and cellular analysis now provide new opportunities for defining new biomarkers and targets.
Intimal lining layer
The lining of the synovium comprising a few cells without a basement membrane and which covers the nonarticular surface of the joint capsule.
Synovial sublining
A loose connective tissue that lies beneath the intimal lining of the synovium.
Pannus
A 'tumour-like' mass of hyperplastic synovial tissue that expands into the joint, invading into bone and cartilage.
(such as tissue inhibitors of metalloproteinases (TIMPs) and inhibitors of serine proteinases (SERPINs)) are also present in the normal joint 20 . The levels and activity of these enzymes can be monitored indirectly by measuring their degradation products in the synovial fluid 21 .
Features of the inflamed joint
The inflamed synovium has been studied at the macroscopic, microscopic and molecular levels. The synovium is the primary target of disturbed immunomodulatory pathways in RA. Rheumatoid synovial tissue appears to be macroscopically hyperplastic and hypervascular (FIG. 1a,b) , while microscopic analysis reveals hyper plasia of the intimal lining layer (FIG. 1c) and the accumulation of inflammatory cells (FIG. 1d) , including T and B lymphocytes, plasma cells, macrophages, neutrophils, mast cells, natural killer cells and dendritic cells, in the synovial sublining 22 . Like the target organs in other autoimmune diseases (for example, Sjögren syndrome and autoimmune thyroiditis), infiltrating T cells and B cells have been demonstrated to form aggregates that have varying degrees of organization and the potential to produce disease-specific ACPAs 23, 24 .
Angiogenesis accompanies this immune cell accumulation, but it occurs in an abnormal manner that results in different patterns of blood vessels in different inflammatory arthropathies 25 . The new blood vessels seem to be in an immature state 26 . They permit increased leukocyte migration, and the synovial tissue transforms into an invading pannus that can cause cartilage and bone destruction 27, 28 . Despite the increased vascular supply, marked hypoxia has been demonstrated in inflamed synovial membranes in vivo 29 . The low tissue partial oxygen pressures in inflamed synovial joint tissue are associated with significant increases in macroscopic synovitis scores and markers of microscopic inflammation, such as CD68 + macrophages and CD3 + T cells in the sublining, and various pro-inflammatory mediators (including TNF, IL-1β, IFNγ and the chemokine macrophage inflammatory protein 3α (MIP3α; also known as CCL20)). When primary synovial fluid cells are exposed in vitro to partial oxygen pressures similar to those in inflamed joints, cell migration is significantly increased, suggesting that hypoxia drives pathological changes in the synovium 26 .
Many of the pathological changes in inflamed synovial tissue are reflected in the synovial fluid, which has also been studied intensively. Inflammation alters the permeability of synovial tissue 30 ; in the RA-affected synovium, the permeability to large molecules is increased, but that to small molecules (for example, urea and glucose) is decreased, an effect that is attributable to a combination of increased vessel permeability, cellular infiltration and synovial hyperplasia. As a result, the total protein content of synovial fluid is higher during inflammation than in the steady state. The molecular weight distribution of the lubrication macromolecule hyaluronic acid is also altered during inflammation, with a shift towards lower molecular weight forms in RA 31 . In addition, rheumatoid joints show increased loss of hyaluronic acid compared with healthy joints, and the mean hyaluronic acid concentration is lower in synovial fluid samples from patients with osteoarthritis (OA) or RA than in those from healthy controls 32, 33 . Synovial fluid samples from patients with inflammatory arthritides have markedly raised cytokine concentrations 34 . The role of cytokines in initiating and perpetuating the synovial inflammatory response continues to be studied intensively, and has already led to the development of several useful therapeutic agents and to the identification of further potential targets 16 . Changes in the cellular infiltrate of RA-affected synovial tissue have long been recognized to be associated with the clinical course of disease, and have been used to identify specific responses to conventional and biologic DMARDs [35] [36] [37] . In summary, the synovial tissue of patients with inflammatory arthritides displays numerous alterations relative to healthy synovial tissue. Thus, the study of synovial tissue is crucial to improving our understanding of these diseases.
Synovial biopsy
The utility of synovial biopsy is clear; the analysis of biopsy-obtained synovial tissue samples has increased our understanding of the pathogenesis of RA, identified potential therapeutic targets, and enabled the evaluation The widespread availability of synovial tissue biopsy procedures and analytical methods throughout the world 52 will inevitably enable a targeted approach to the identification of synovial biomarkers. The advent of new proteomic, transcriptomic and genomic technologies, and the ability to combine clinical and radiological markers with these technologies, will facilitate progress in this area. The omics approach has been usefully applied to the identification of key players and protein interactions in several diseases. Studying the genome, RNA expression or protein expression each have different biases, and combined approaches could arguably lead to a more accurate assessment of important protagonists 104 . Proteomics offers the advantage that the functional units (that is, the proteins) of the cell are being studied directly, and this approach is likely to provide information that most accurately reflects what is actually happening in the synovium. Technologies such as SomaLogics that have the power to measure thousands of proteins in small volumes of tissue have the potential to enable a more complete characterization of the protein networks that underlie diseases such as rheumatoid arthritis (RA) 160 . Furthermore, new technologies for protein separation, processing and identification are expected to increase proteome coverage. In RA, the proteomics approach has so far focused on peripheral blood mononuclear cells, serum and synovial fluid 66, 67, 139 ; the possibility that the synovial tissue itself might hold the key to elucidating the underlying disease-associated protein networks has yet to be fully exploited by proteomic studies.
In relation to transcriptomic analysis, microarray technology has, to date, been the most frequently used strategy in the field of biomarker research. This technology facilitates the identification of candidate genes that are involved in pathophysiological processes. However, gene expression levels do not always predict protein levels owing to transcriptional and translational regulatory mechanisms and the activity of protein-degradation processes 17 . Microarrays contain probes for thousands of different genes, and they are suitable for screening large cohorts; however, the high-throughput techniques used in transcriptomics also enable the detection of significant gene-expression differences within modestly sized cohorts 161 . Transcriptomic analysis is already being used to examine the gene signatures of synovial tissue, and such investigation is augmented by the newer sequencing technologies that enable deeper transcriptional coverage than do microarrays and that include spliced variants. Several studies have demonstrated that microarray technology is a useful and practical methodology for studying gene expression in RA, and have characterized gene-expression patterns in the synovia of patients with RA (see the section of the main text entitled 'Gene-expression profiles') 162, 163 .
Arthroplasty
Surgical reconstruction or replacement of a synovial joint.
Arthroscopic biopsy
Minimally invasive procedure to examine a synovial joint using an endoscope.
of current and new treatments . Synovial tissue analysis might also provide insights into the mechanism of action of a given agent 58 . This section discusses how synovial biopsy and analysis are carried out, and summarizes the main areas in which synovial tissue analysis has proven informative.
Retrieving synovial tissue samples
Synovial tissue can be obtained by needle biopsy, arthroplasty, arthroscopic biopsy, or using ultrasound to guide the biopsy needle or grasping forceps 58 
(FIG. 2).
Arthroscopic biopsy enables the direct visualization of the synovium, and the operator can select an area of synovium to biopsy. By contrast, ultrasonography enables the indirect visualization of synovial thickness, and synovial vascularity can simultaneously be assessed by Doppler ultrasonography when selecting a suitable biopsy site. Although blind biopsy has been validated, arthroscopic biopsy and ultrasound-guided biopsy procedures are favoured by the majority of investigators for proof-of-concept experiments, as sampling is more specific for synovial tissue than connective tissue using these methods 52 . Arthroscopic and ultrasound-guided biopsy procedures are safe and well-tolerated. Data from 15,682 arthroscopies performed by rheumatologists revealed a complication rate of 0.9% for haemarthrosis, 0.2% for deep vein thrombosis, and 0.1% for both wound infection and joint infection 59 . These data were reproducible at other centres, and the overall complication rate was less than 0.3%. Similarly, a systematic review reported an overall major complication rate of 0.4% for ultrasound-guided biopsy procedures 60 .
Synovial tissue analysis
Questions remain about the best location from which to obtain a biopsy sample within a given joint. In particular, concerns have been raised that mediators of inflammation might be differentially expressed in different parts of the same joint, particularly in the cartilagepannus junction (CPJ) versus non-CPJ sites, which are known to behave differently 61 . However, the numbers of T cells 62, 63 and plasma cells 63 , and the expression levels of several MMPs 63 and granzymes 63 , are reported to be similar in biopsy samples from CPJ and non-CPJ sources.
One study did find a difference for macrophages 64 , but other studies did not replicate this finding 62, 63 . Studies examining the optimal number of synovial tissue specimens required for reproducible research studies suggest that at least six biopsy specimens should be obtained 58, 65 . Although immunohistochemical analysis of synovial tissue (FIG. 3) has a minor clinical role in the differential diagnosis of arthritis (for example, infectious, granulomatous, infiltrative diseases or crystal arthropathies), the identification of biomarkers that could be used for diagnosis or for predicting disease progression and response to treatment remains an unmet challenge. Therefore, studies of the synovium have expanded beyond immunohistochemistry to involve methods of tissue digestion, homogenization and whole-tissue culture (FIG. 4) . Methods of examining synovial tissue at a molecular level include detailed omics technologies
. For such analysis, the synovial tissue obtained from the joint is placed on saline-dampened gauze, snap-frozen in the cryoprotective optimal cutting temperature (OCT) compound or placed directly into an RNA-stablizing solution (such as RNAlater).
Synovial fluid samples are centrifuged, and a cell pellet can be isolated or separated using a Ficoll gradient to provide synovial fluid mononuclear cells. Several prognostic biomarkers of RA have been identified in synovial fluid and validated in serum samples 66 . Studies using this strategy first identified proteins that were of potential interest in the synovial fluid, and then searched for antibodies to these proteins in the plasma 67 . The approach of 
Positional memory
Cells might demonstrate different DNA 'fingerprints' depending on the site of the body at which they reside.
Undifferentiated arthritis
Inflammatory oligoarthritis or polyarthritis that does not conform to any of the recognized inflammatory arthritis types.
obtaining and analysing different types of samples from the same patient might be useful in future experiments of synovial tissue, and the results of such research might be more easily translated into clinical practice, as serum samples can be obtained in a relatively non-invasive manner. It is important to note that although synovial fluid might reflect the synovial compartment better than does blood, it still provides only indirect information, and therefore studies of synovial tissue are essential 68 . Although most research studies of synovial tissue biopsies have involved patients with RA, which is the focus of this Review, synovial tissue sampling might also be useful in the context of other inflammatory arthropathies such as psoriatic arthritis [68] [69] [70] [71] .
Main areas of progress
As mentioned above, synovial tissue research has fuelled progress in several key areas; these areas are summarized in TABLE 1 and discussed in more detail here.
Insights into the pathogenesis of synovitis
The importance of directly analysing synovial tissuethe target tissue in RA -is evident from studies investigating the pathogenesis of RA. For example, T helper 17 (T H 17) cells are expanded in the blood of some patients with RA, and this finding provided the rationale for clinical trials of anti-IL-17 monoclonal antibodies; however, as limited T H 17 expansion occurs within the synovium of patients with RA, this therapeutic approach had little effect 72 . Indeed, studies of synovial fluid and synovial tissue from patients with RA have shown an enrichment of so-called ex-T H 17 cells at the site of inflammation 73 . This finding might explain the failure of anti-IL-17 therapy in some patients as the differentiated T cells no longer produce IL-17. Further emphasizing the importance of direct synovial tissue analysis is the fact that no circulating biomarkers have yet been identified that can provide a readout of the activity of the primary invasive cells in RA, the FLSs 74 . Synovial tissue analysis has also revealed some surprising findings regarding pathogenic mechanisms involved in RA. One study of paired biopsy samples taken from the inflamed knee joint and an inflamed small joint of patients with RA demonstrated similar mean cell numbers for all markers investigated in the synovial sublinings of both tissues 75 . Of further note, patients with clinically evident disease that manifests at small joints have been shown to have similar -albeit less pronounced -abnormalities in clinically uninvolved knee joints 64, 75, 76 . However, hyperplasia of the intimal lining layer seemed to depend on local processes; different joints showed no similarity in terms of the numbers of intimal macrophages or FLSs 64 . Consistent with these findings, in RA, the FLSs from different joints of the same patient show distinct DNA methylation and transcriptome signatures, as well as differences in FLS invasiveness, depending on their positional memory 77, 78 .
Early arthritis and disease stratification
Since 2002, cohorts of patients with early arthritis have been gathered, and have provided clinical, histological, DNA-level, mRNA-level and proteomic data; such cohorts represent instrumental resources for investigating early disease 79 . Synovial tissue analysis is beginning to have an impact on our understanding of early arthritis. Although some progress has been made in terms of diagnosing RA earlier, signs of joint destruction can already be present at the time of diagnosis and so developing our understanding of early disease is important 80 . We know today that early, aggressive treatment is more successful than is delayed treatment 81, 82 , and a 'window of opportunity' is suggested to exist, during which RA can be most successfully treated. Therefore, the use of biomarkers to secure a diagnosis as early as possible will enable treatment in the most timely manner and will secure the best outcomes 83 . Patients with undifferentiated arthritis might benefit most from early diagnosis. Although ACPA detection is reasonably specific (96%), the diagnostic sensitivity of ACPAs in early arthritis is 57% 81 , and up to 30% of patients with RA never develop ACPAs, highlighting the need for alternative biomarkers 84, 85 . An association has been defined between the presence of circulating ACPAs and the subsequent development of RA in individuals with arthralgia 86 , and of bone erosions in patients with early untreated arthritis 87 . However, a positive ACPA status in those with arthralgia is associated with the subsequent development of arthritis in only 20-30% of individuals after 30 months of follow-up 88, 89 , further emphasizing the need for additional biomarkers. 
Disease stratification
The concept that a disease can be classified into distinct subsets that exhibit differential outcomes and responses, and that can each be labelled by a biomarker or a combination of biomarkers.
A delay in diagnosing RA could arise from either a lack of a definitive biomarker or a failure to meet current diagnostic criteria, and these criteria have a considerable reliance on biomarkers; thus, further research into specific susceptibility biomarkers is warranted. Two studies published since 2015 have identified circulating biomarkers of RA in patients who lack detectable circulating ACPAs; this subset of patients is an important group to study, and data from these patients might contribute greatly to our understanding of disease pathogenesis 90, 91 . Synovial tissue analysis could be key to the identification of the required biomarkers.
Cohorts of individuals who are at risk of developing arthritis have been the subject of much research. One potential corollary of such studies is the promise of a cure for RA, or a preventive approach that could detect and therapeutically target the initial breach of self-tolerance 92 . The synovial tissue of patients who are at risk of arthritis has been examined in two relatively small studies. Little evidence of synovitis was found in the first study 88 , and subtle T cell infiltration was noted in the second 89 . Further study of synovial tissue samples from at-risk individuals is required, as is the analysis of other tissues, such as the lung and lymph nodes, which might be important in the very early stages of arthritis as they are the first sites at which antigen is presented 93, 94 .
The analysis of synovial tissue samples from patients with early RA has provided important insights. In initial studies, the synovia of patients with early disease have shown few molecular differences when compared with synovia of patients with late disease 23, 95 . However, a study published in 2012 identified a highly expanded, specific T cell clone in the synovia of patients with early RA, which underlines the importance of T cells in early-stage disease 96 . Another study has indicated that epigenetic changes occurring in FLSs over time might define the different stages of RA after clinical onset 97 . Furthermore, in a preliminary report published in 2016, synovial tissue obtained by ultrasound-guided biopsy from unselected treatment-naive patients with early arthritis showed increased expression of the macrophagederived chemokines CXC-chemokine ligand 4 (CXCL4; also called platelet factor 4) and CXCL7 (platelet basic protein) only during the first 3 months of symptomatic arthritis and not later in the disease 98 . In addition to identifying potential pathogenic mechanisms, synovial tissue biopsy might be useful for informing differential diagnosis in early inflammatory arthritis, as suggested by a study in which synovial CD22 and CD38 expression could distinguish patients with RA from those with non-RA disease 99 . The use of synovial biomarkers for early disease stratification was also reported in a study of 50 patients with early arthritis who had undergone synovial biopsy at inclusion and were followed for 2 years 100 . The focus was on the angiogenic processes involved in the initiation and perpetuation of synovial inflammation, in particular vascular endothelial growth factor (VEGF) and angiopoietins 1 and 2, and their tyrosine kinase receptors VEGFR and tyrosine kinase with Ig and EGF homology domains 2 (TIE2; also known as angiopoietin 1 receptor). The expression of TIE2 was significantly increased in the synovia of patients with erosive disease compared with the synovia of patients who had self-limiting disease, and the expression of activated, phosphorylated TIE-2 was significantly increased in patients with persistent non-erosive disease or persistent erosive disease compared with patients who had self-limiting disease. In addition, the activation of JUN N-terminal kinase (JNK) is elevated in the synovia of patients with early RA relative to the synovia of patients with undifferentiated arthritis, before the classification criteria for RA are met 101 . Together, these studies indicate that synovial tissue analysis can provide information relevant to disease diagnosis.
Only a limited number of studies have analysed synovial tissue from patients with early RA, and so the use of synovial tissue markers in early diagnosis is clearly still evolving. Although more research is needed, these studies suggest that a synovial biopsy at disease presentation could be a useful tool for both patients and physicians, as it could enable the stratification of early RA into short-duration, self-limiting disease (which may be erosive or non-erosive) versus severe, persistent and destructive inflammatory disease, thereby informing the most appropriate treatment strategy 102, 103 . This personalized medicine approach tailors treatment on the basis of biomarkers and so-called 'disease signatures' (REF. 98 ), which enable . The sensitivity and specificity of disease stratification could theoretically be improved by using a combination of biomarkers. For example, a positive clinical response of RA to anti-TNF treatment with etanercept has been predicted using a biomarker signature comprising 13 autoantibodies and 11 cytokines. This study included three ethnically distinct populations, and for North Americans it demonstrated a positive predictive value of 71%, although independent validation is required 11 . Disease stratification is important as therapies are commonly selected on a trial-and-error basis but less than 50% of patients with RA experience a 50% improvement in their arthritis in response to any single biologic therapy [106] [107] [108] . In the time that an ineffective treatment is administered, the disease might progress, and patients could potentially experience unnecessary adverse events. Therefore, biomarkers that predict response to a given treatment will be of great clinical utility. Synovial biomarkers are likely to be of the greatest clinical utility, and a great deal of work has concentrated on studying features of the inflamed, RA-affected synovium before and after treatment. Examples of such studies, and others that have analysed the ability of synovial tissue biomarkers to predict disease prognosis and response to therapy, are summarized in the next section.
Different types of synovial biomarker
Lymphocyte aggregates. A detailed discussion of lymphocyte aggregates is beyond the scope of this Review, and the topic has recently been discussed in detail elsewhere 109 ; however, we wish to briefly highlight the potential biomarker role of these structures here. A number of studies have addressed whether lymphocyte aggregates of synovitis are associated with clinical phenotype or the development of persistent, erosive disease. In two large studies, lymphocyte aggregates were found in approximately 30% of patients with established RA but did not associate with a clinical phenotype 110, 111 . Similarly, the presence of lymphocyte aggregates in patients with early arthritis did not predict an aggressive disease course, and aggregates were rapidly diminished by several antirheumatic treatments 112, 113 . In addition, the number of lymphocyte aggregates is reported to be predictive of the clinical response to infliximab treatment 112, 114 . Positivity for lymphocyte aggregates increased the power of a prediction model that included baseline disease activity evaluated by 28-joint disease activity score (DAS28), ACPA positivity and synovial TNF expression 112 . Taken together, these studies suggest that although lymphoid aggregates may not enable the stratification of disease into subtypes, they might represent a biomarker of treatment response.
Lymphocytes. Simple cell counts (or cellular infiltrates) were recognized as RA-associated synovial tissue biomarkers more than 20 years ago. In a study published in 1989, T cell numbers were shown to decrease after at least 6 months of gold treatment, and the ratio of T H cells to suppressor T cells or cytotoxic T cells was found to be reduced in patients who were treated successfully 35 . Furthermore, the number of biopsy samples in which B cells could be identified decreased from 36% before successful treatment to 7% after treatment 35 .
Further evidence that the abundance of synovial lymphocytes (as assessed by staining for cell markers) represents a biomarker of treatment response comes from studies of the following RA therapies: 16 weeks of methotrexate, which caused a decrease in the synovial expression of markers of T cells (CD3 and CD8) and plasma cells (CD38) 115 53, 116, 117 . The changes in CD68 + macrophage numbers after rituximab treatment have been replicated independently in another centre 118 . By contrast, one other group showed reductions in B cell numbers with minimal or no change in macrophages and T cells 119 ; this variation in findings is possibly explained by differences in patient populations, methods for immunohistochemistry or analysis such as digital image analysis.
Macrophages. Although macrophages were not included in the 1989 study described at the start of the previous section 35 , the most convincing evidence for a cellular biomarker of treatment response points to the macrophage marker CD68. This evidence comes from many studies, including those of patients receiving the following RA therapies: 2 weeks of prednisolone, which reduced CD68 + macrophage abundance in the synovial sublining 41 ; 12 weeks of gold therapy, which was associated with an abundance of changes in all synovial layers independently of the site of synovial biopsy 120 ; various durations of treatment with methotrexate or gold 121 , for which the reduction in CD68 + macrophage numbers in the synovial sublining was particularly pronounced ; various durations of infliximab treatment, which reduced CD68 + macrophage numbers in the synovial sublining 44, 122 ; anakinra, over 24 weeks, which reduced the size of the intimal CD68 + macrophage population 42 ; and various durations of rituximab treatment, which reduced the abundance of intimal lining CD68 + macrophages in responders 53 . One study has systematically investigated the utility of synovial sublining-localized CD68 + macrophages as a candidate biomarker across different interventions and kinetics, and found that changes in the numbers of these cells correlate with clinical improvement independently of the therapeutic strategy; the number of CD68
+ macrophages decreased as disease activity reduced (as measured by DAS28), thus demonstrating that such cell counts could be used as a biomarker of therapeutic response 123 . This finding was confirmed in a multicentre study that reported excellent intercentre agreement 118 . Furthermore, the sensitivity to change of synovial CD68 expression is good for both DAS28 and sublining macrophages after active treatment, including rituximab 124 ; in addition, it has been shown that DAS28 is more susceptible to placebo effects than synovial CD68 expression 125 . Therefore, while we do not propose to focus on synovial biomarkers without clinical assessment, using this biomarker has been shown to be less susceptible to the placebo effect and expectation bias 123, 125 . This work has led to the development of a simple decision tree to inform 'go/no-go' decision-making in drug development, which incorporates clinical assessment, mechanism of action and synovial CD68 expression and has been used in the evaluation of numerous compounds since its proposal 51 . In a ballot at the Outcome Measures in Rheumatology (OMERACT) 9 conference general assembly in 2008, 59% of the delegates agreed that CD68 expression in synovial tissue is less susceptible to a placebo effect and expectation bias than clinical evaluation, compared with 13% who disagreed 118 .Therefore, substantial evidence exists to suggest that synovial CD68 expression in synovial sublining macrophages demonstrates validity, reliability and feasibility as a biomarker of disease activity and could therefore be used to assess the therapeutic efficacy of novel treatments 118, 123, 125, 126 . All of these studies have used the same standardized techniques of immunohisto chemistry, which have been extensively validated across multiple EULAR European Synovitis Study Group centres 118 . By contrast, three studies from the same centre reported minimal or no change in macrophage cells, possibly owing to the use of different methology; in studies of rituximab 119 , abatacept 127 and, more recently, the signal transducer and activator of transcription (STAT) inhibitor tofacitinib 128 some reduction in sublining macrophages was apparent but this reduction was not statistically significant. A proof-of-concept study of a CC-chemokine receptor 1 (CCR1) antagonist, used at high doses to achieve high levels of receptor occupancy, did show a reduction in macrophages, CCR1 + cells and a trend towards clinical response 129 . Additionally, in the single study in which similarly high levels of CCR1 receptor occupancy were achieved there was clear evidence of clinical efficacy 130 , supporting the predictive value of this approach.
Cytokines. As mentioned in the 'Features of the inflamed joint' section, the increased expression of several cytokines in inflamed synovial tissue is well established. Indeed, synovial TNF and IL-6 concentrations correlate with disease activity, independently of disease duration 26 . With regards to the effects of treatment on cytokines, the expression levels of IL-1β and TNF were 40% (95% CI 18-56%) and 52% (95% CI 10-74%) lower, respectively, following prednisolone therapy compared with placebo treatment 41 . Notably, this effect was mainly attributable to changes in the synovial sublining, and seemed to correlate with clinical improvement 41 . Significant changes in cytokine expression have also been reported in the synovial lining, perivascular tissue and connective tissue after 12 weeks of gold treatment 35 . In the intimal lining layer, the levels of IL-1α, IL-1β and IL-6 were significantly reduced after treatment, and this reduction seemed to correlate with clinical response. TNF was also reduced in all three areas, but the reduction in the synovial lining was not statistically significant 35 . In another study, TNF levels were only slightly reduced in synovial samples from patients who received 16 weeks of treatment with either methotrexate or leflunomide 40 . IL-1β levels were only moderately reduced in the leflunomide-treated patients, whereas reductions in the methotrexate-treated patients were significant, which potentially reflects the different mechanisms of action of these DMARDs 40 . Another study has also reported that the expression of IL-1β (but not that of IL-1α) is significantly reduced after 16 weeks of treatment with methotrexate and found that this reduction correlated with clinical response 115 . As highlighted above, targeting cytokine signalling pathways, for example the STAT pathway, is an interesting and novel approach. Tofacitinib has shown significant clinical benefit in patients with RA and is associated with a significant reduction in expression of phosphorylated STAT in synovial tissue, which suggests that the level of phosphorylated STAT could be a useful biomarker of response to this therapy 128 . Although not itself a cytokine, acute serum amyloid A (A-SAA) regulates the expression of cytokines and is expressed in RA synovial tissue, where it has a role in inducing angiogenesis, cell-matrix interactions, and the expression of chemokines and MMPs 131 . Furthermore, blockade of the A-SAA receptors scavenger receptor class B member 1 (SRB1) 131 and Toll-like receptor 2 (TLR2) inhibits FLS migration and invasion in synovial explants from patients with RA 132 . Importantly, baseline serum A-SAA levels independently correlate with the 28-joint swollen joint count and 1-year radiographic progression in patients with RA 20 . Therefore, serum A-SAA is a promising biomarker of disease activity, warranting further investigation of its expression in the synovia of patients with RA 133 .
Chemokines. Leukocytes are attracted to target tissues by soluble chemotactic cytokines termed chemokines, which are released from activated cells in the tissue to stimulate leukocyte migration through the endothelial barrier 134 . The chemokine monocyte chemotactic protein 1 (MCP1; also known as CCL2), among others, is expressed abundantly in both serum and synovial tissue samples from patients with RA 49 . The development of clinical signs of synovial inflammation in RA is specifically associated with the increased synthesis of CXCL8 (also known as IL-8) 135 , and the expression of both CXCL8 and MCP1 in synovial tissue (both the lining and sublining) reflects response to therapy in patients with active RA who have received infliximab; the synovial expression of growth-regulated protein-α (GROα), RANTES (also known as CCL5) and MIP1β (also known as CCL4) was also reduced but not to a significant extent 44 . Thus, chemokines could represent a target and a biomarker of treatment response. Indeed, a =proof-of-concept study of an oral CCR1 antagonist in patients with RA showed a trend towards clinical improvement and a concomitant, significant reduction in synovial macrophage numbers and chemokine expression, suggesting that targeting CCR1 results in changes that could also represent biomarkers of response to this antagonist 129 . S100 proteins. Similarly to some cytokines and chemokines, the S100 protein family -which comprises closely related, low-molecular-weight (9-14 kDa) acidic calcium-binding proteins -have pro-inflammatory effects, and they are overexpressed in inflammatory compartments. S100 proteins are involved in calcium-dependent cell activities such as cytoskeleton regulation, and cell migration and adhesion, and they also have extracellular roles 136 . S100A8 (also known as MRP8) and S100A9 (also known as MRP14) regulate myeloid cell function and control inflammation 137 , and S100A12 (also known as MRP6) has important activities in relation to innate and acquired immune responses 138 . One study using quantitative proteomics demonstrated an association between the severity of joint erosion in RA and the levels of S100A8, S100A9 and S100A12 in both synovial fluid and serum samples 139 ; this potential role of S100 proteins as synovial biomarkers requires further study.
Adhesion molecules. The expression of intercellular adhesion molecule 1 (ICAM1) is significantly reduced in patients with RA who are treated with either leflunomide or methotrexate 40 . Notably, the significant decrease in ICAM1 expression was seen only in those who responded to treatment. The expression of vascular cell adhesion molecular 1 (VCAM1) was reduced in both treatment groups, but this reduction was significant only in the leflunomide-treated patients 40 .
Another study demonstrated that the expression of VCAM1 and E-selectin was significantly reduced after 16 weeks of treatment with methotrexate, but in this study the changes in ICAM1 expression did not reach statistical significance 115 . Similarly, treatment with infliximab has been shown to reduce VCAM-1 and E-selectin expression in repeat biopsies taken 4 weeks after treatment 38 . Interestingly, the effect of anakinra might be dosedependent, as patients taking a dose of 150 mg per day -but not those receiving a lower dose of 30 mg per day -were shown to have reduced synovial expression of E-selectin, ICAM1 and VCAM1 (REF. 42 ). Together, these studies highlight the biomarker role of synovial adhesion molecule expression.
Mediators and products of bone, cartilage and synovial tissue degradation. Serum levels of collagen biomarkers and MMPs are known to predict radiographic progression in RA, and therefore could represent prognostic biomarkers 27, 140 , but could the synovial levels of these molecules also be a biomarker?
Although MMPs are present in normal synovial fluid, their concentrations are increased in synovial fluid from patients with RA, psoriatic arthritis and OA 17, 141, 142 . MMP1, in particular, might be a synovial biomarker of treatment response, as suggested by a study reporting that monotherapy with methotrexate or leflunomide significantly reduced the expression of MMP1 and the MMP1:TIMP1 ratio in synovial tissue samples from patients with RA after 4 months of treatment 40 . Notably, the changes were more pronounced in patients who fulfilled the ACR20 response criteria 40 .
In addition to studies of matrix-degrading MMPs, a number of studies have analysed the effects of immunomodulatory treatment on synovial mediators of bone destruction. Treatment with either infliximab or etanercept increases the expression of osteoprotegerin (OPG; also known as TNFRSF11B) in synovial tissue, but had no effect on the expression of receptor activator of nuclear factor-κB ligand (RANKL; also known as TNFSF11), resulting in an increased OPG:RANKL ratio 48 . By contrast, rituximab induces a 99% decrease in the numbers of receptor activator of nuclear factor-κB (RANK)-positive osteoclast precursors and 37% decrease in RANKL expression, but only a nonsignificant reduction in synovial OPG expression 143 . However, not all RA therapies induce changes in the levels of these bone-destructive mediators; indeed, abatacept does not significantly affect the synovial levels of mRNA expression of OPG, RANK or RANKL 127 , suggesting that the biomarker role of these synovial molecules might only be relevant in specific settings.
Antigens and antibodies. The expression of antigenic proteins has been described in synovial tissue samples from patients with RA. For example, one study reported that deiminated protein -such as the α-and β-chains of fibrin -present in RA-affected synovia seem to be major antigenic targets of ACPAs 144 . In addition, anti-Sa antibodies that recognize deiminated vimentin have been isolated from RA-affected synovia and seem to be specific to RA 145 . Intracellular citrullinated proteins that colocalize with ACPA reactivity have also been identified in synovial tissue from patients with RA 146 , but the presence of citrullinated antigens in synovia is not specific to RA 24 . Finally, anti-fillagrin antibodies are produced by local plasma cells that are resident in the RA pannus 147 , and thus could also be synovial biomarkers of RA.
Gene-expression profiles. Most of the previous discussion has focused on protein-level data, predominantly from immunohistochemical analyses; however, as mentioned above and discussed in BOX 1, studies have also identified changes in synovial gene-expression profiles, and these profiles could represent biomarkers. An example of how transcriptomic data can be clinically useful comes from a study that used these data to create a rulebased classification that could differentiate between RA and OA 148 . In addition, gene-expression variance among patients with RA has been described for genes involved in processes such as cell proliferation, cell survival, angio genesis and the regulation of inflammation 149 . Several studies have investigated links between gene-expression profiles and treatment response; for example, genes involved in inflammation shown to be upregulated in pretreatment biopsy-obtained synovial tissue from patients with RA who subsequently responded to anti-TNF therapy 150 . In a larger follow-up study, RNA analysis of pretreatment synovial tissue from patients with RA who were positive for lymphocyte aggregates revealed that 38 transcripts were associated with clinical response to infliximab treatment 114 . A study of paired synovial tissue samples taken from patients with RA before and 12 weeks after initiation of adalimumab treatment also identified genes that were differentially expressed in samples from responders and non-responders 151 . These genes could be split into two distinct families: genes involved in the regulation of immune responses and genes involved in the regulation of cell division. To confirm the microarray findings, the synovial expression of selected molecules was assessed using specific antibodies, and the expression of IL-7 receptor α-chain (IL-7Rα), CXCL11, IL-18, IL-18 receptor accessory protein (IL-18RAP) and the proliferation marker MKI67 was found to be significantly higher in poor responders than in moderate and good responders. Thus, these findings link geneexpression changes to protein-level changes and, consistent with studies discussed above, they emphasize the role of molecules involved in cytokine and chemokine signalling as potential biomarkers of treatment response 151 . Gene-expression analyses also support the role of macrophages and T cells as biomarkers of treatment response. For example, a study of paired synovial biopsies performed in patients with RA before and after initiation of rituximab treatment revealed that clinical responders demonstrated higher synovial expression of macrophage-associated and T cell-associated genes, whereas those with a poor clinical response showed higher synovial expression of IFNα and genes associated with matrix remodelling 152 .
Challenges in biomarker identification
Most studies of serial synovial biopsies have been performed on patients with known diagnoses and have aimed to investigate response to treatment. There remains a critical need to identify diagnostic biomarkers that can be used in clinical practice. Biomarkers could reduce the time taken and patient numbers required to evaluate the potential efficacy of new drugs 51, 153 . The number of patients with active disease who are eligible to participate in studies is limited. As with all trials, the number of patients who are to be put at risk by exposure to drugs at an early stage of drug development, as well as to be placed on placebo, are restricted by ethical considerations 154 . Although finding biomarkers in peripheral blood is attractive because obtaining blood samples is more feasible and less invasive than synovial biopsy, the inflamed synovium is the ultimate target of inflammation and should thus be a rich source of potential biomarkers. Furthermore, many confounding factors might interfere with peripheral blood profiles. Some authorities have suggested that a more targeted approach to searching for serum markers should first involve the identification of potential biomarkers in the inflamed synovial joint, and then the study of these biomarkers in the serum 155 . Such an approach has demonstrated clinical utility in patients with RA in a study reporting that candidate peripheral biomarkers of synovial pathotype predicted response to biologic therapy 156 . New technologies are advancing synovial tissue analysis, but several issues remain to be addressed. Although new technologies have enabled faster and more complete analyses of proteins, the high complexity of proteins and protein isoforms in the synovial joint makes the interpretation of 'shotgun' proteomic data challenging. The interpretation of data from microarrays is also problematic; for example, three widely used microarray platforms have demonstrated poor reproducibility 157 . In addition, as array datasets contain high levels of background signals, they have decreased sensitivity to transcripts that are present in low numbers 158 . Cost and time are also important issues; for example, the development of high-quality immunoanalytical assays can be slow and expensive, which limits the verification of candidate biomarkers, despite the increase in the availability of means to biopsy synovial tissue. In addition, when data from control synovial tissue specimens is available, OA is often used as a disease control, although it is increasingly recognized that OA has an underlying inflammatory response, albeit one that is limited and less associated with specific autoimmunity than is the response that underlies RA 159 . These issues perhaps explain why although a great many genomic biomarkers exist that can predict response to treatment or who is most at risk of adverse events in many areas of medicine, rheumatology seems to have experienced only limited benefit from this emerging field. Future progress in identifying genomic biomarkers, and other types of biomarker, will probably be fuelled by synovial tissue analysis, which has not yet been extensively performed in some areas; for example, although many studies have attempted to identify gene-expression profiles that can predict response to anti-TNF treatment, to our knowledge only those reported above have used synovial tissue to search for these 112, 114, 151 .
Conclusions
Synovial tissue represents the target tissue of autoimmune arthritides such as RA. New, safe methods of obtaining samples of synovial tissue are becoming more widely available. In this Review we have highlighted those studies that analyse the cellular and molecular characteristics of RA synovial tissue and how the results have advanced the field in terms of patient stratification, therapeutic target development and identification of biomarkers of response to therapy. In addition, we have reviewed the use of synovial tissue analysis as an outcome measure for clinical trials in RA. Finally, the future application of rapid advances in molecular technologies to synovial tissue analysis will probably lead to major benefits for patients with RA.
